RESEARCH-USE BIOSIMILAR ANTIBODY
Lexatumumab
Monoclonal antibody · IgG1
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
TARGETTNFRSF10B
YMonoclonal antibody
CATALOGSC-BS-432
CATALOG NUMBERSC-BS-432
MOLECULAR WEIGHTApprox. 143.48 kDa
PRODUCT FORMATMonoclonal antibody
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
Lexatumumab is a recombinant research-use antibody directed against TNFRSF10B.